Valitor to Present at the Association for Research in Vision and Ophthalmology Annual Meeting
BERKELEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Valitor, a biotechnology company engineering better medicines to conquer drug limitations, today...
Year: 2023
Goodness Growth Holdings to Report Fourth Quarter and Full Year 2022 Results on March 30, 2023
MINNEAPOLIS, March 23, 2023 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF),...
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
Collaboration builds off clinical data demonstrating rigosertib’s activity against PLK1 and may inform a precision medicine approach towards rigosertib’s evaluation...
Nautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein...
Solid Biosciences Provides Fourth Quarter and Full-Year 2022 Business Update and Financial Results
- Completed the acquisition of AavantiBio, creating a precision genetic medicines company with a focus on cardiac and neuromuscular diseases;...
Vaccinex, Inc. to Present at the 2023 AAIC Advancements: Immunity Conference
March 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s Disease and Alzheimer’s DiseaseROCHESTER, N.Y.,...
iCAD’s Breast AI Suite Empowers Customers to Lead the Way in Support of FDA’s National Breast Density Reporting Standard
iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual ConferenceNASHUA, N.H., March 23, 2023 (GLOBE...
BioAdaptives Announces Signing of Letter of Intent With World Wellness, LLC for the Launching of Weight Management System Including an AI Supported Body Composition Measuring App and New Health Products
FIT YOUR OUTFIT (FYO) the App That Scientifically Measures and Tracks Body Composition With a Single Photo From Your Smartphone...
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
Additional poster presentation to detail high-dose cohort safety data from Phase 2a trial of tegoprubart in IgA Nephropathy (IgAN)IRVINE, Calif.,...
Pilot Randomized Controlled Trial Validates Daxor BVA-100® Diagnostic for Heart Failure Patients
BVA Feasibly Guides Fluid Management with Greater Accuracy than Traditional MeansResearchers Conclude that a Larger Powered RCT is Warranted Oak...
electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury
Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury, decrease anxiety and improve motor function...
Nexcella, an Immix Biopharma Subsidiary, Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating NXC-201 Outpatient CAR-T Treatment Potential
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,...
Jasper Therapeutics Appoints Daniel Adelman, M.D., as Acting Chief Medical Officer
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on...
Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023
Media Release 2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to...
Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting
Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients Results from Phase 3...
David Stemler joins CultHealth as Chief Creative Officer
NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- CultHealth, an Indegene company, has appointed David Stemler as Chief Creative Officer....
Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development...
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapyThis potentially enables treatment for patients...
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
- Data from the Global, Multiple Ascending Dose Phase 1/2 DELIVER Clinical Trial Anticipated in the Second Half of 2023...
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1 Trial for SHP2 Inhibitor BBP-398 in Combination with Bristol Myers Squibb’s OPDIVO® (nivolumab)
– BBP-398, an investigational SHP2 inhibitor, is a potentially best-in-class therapy for use in combination approaches, which is shown by...